Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer
June 20 2016 - 4:15PM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced that
Murdo Gordon has been appointed executive vice president and chief
commercial officer, a newly created position, effective June 21,
2016. Gordon will be responsible for leading the execution of
commercial strategy across geographies. In this role, he will lead
our Worldwide Markets in addition to a new Worldwide
Commercialization team. Gordon will continue to report to Giovanni
Caforio, M.D., chief executive officer, and remain a member of his
Leadership Team. Gordon most recently co-led the commercial
organization as Head of Worldwide Markets.
“Murdo has demonstrated tremendous success driving commercial
excellence at Bristol-Myers Squibb, and built strong relationships
with our markets across the world,” said Caforio. “Murdo has made
significant contributions to our success in Immuno-Oncology and
Eliquis, and I am confident his leadership will help drive
continued growth and deliver our medicines to more patients
faster.”
Gordon joined Bristol-Myers Squibb in 1989 and spent the first
14 years at the company in Canada where he held positions of
increasing responsibility in sales and marketing. Gordon moved into
the company’s U.S. operations in 2003 where he held senior
commercial leadership positions in cardiovascular, neuroscience and
market access. He led strategy and commercial operations as senior
vice president for U.S. Oncology and Immunoscience from 2011 to
2013, and served as president, U.S. from 2013 to 2015. Murdo is a
member of the Board of Directors of RWJBarnabas Health and received
a BSc in Cell and Molecular Biology from Concordia University,
Montreal, and also attended the General Management Program, CEDEP
at INSEAD, Fontainebleau, France.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160620006291/en/
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorInvestors:Bill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024